Biased Ligands. Better Drugs.

TRV027 Phase 2a hemodynamics study summary

TRV027, a β-arrestin biased ligand at the angiotensin 2 type 1 receptor, produces rapid, reversible changes in hemodynamics in patients with stable systolic heart failure. Presented at 2013 American College of Cardiology meeting

David G. Soergel MD, Ruth Ann Subach PharmD, Ian E. James PhD, Conrad L. Cowan PhD, Maxine Gowen PhD and Michael W. Lark PhD

View PDF

Copyright © Trevena, Inc.